However, future studies are needed to delineate the presence of p-tau epitopes that are emerging as fluid-based biomarkers in AD, e.g., Thr181 and Thr217, early, soluble p-tau sites that cause detachment of tau from microtubules, e.g., Ser214, and other p-tau sites that enhance tau seeding capacity, e.g., Ser262. This evidence concerns the gene MAPT and Alzheimer disease.